Corporate Highlights and Financial Results for 2025

BioVersys AG announced its full‑year 2025 results on 18 March 2026. The company reported a positive financial performance that aligns with its clinical progress, particularly the advancement of BV100 into a pivotal Phase‑3 trial for hospital‑acquired bacterial pneumonia (HABP) and ventilator‑associated bacterial pneumonia (VABP). The results include:

  • Revenue and profitability: The company achieved a modest increase in operating income, driven by the release of new contractual income related to the Phase‑3 study of BV100 and the continuation of existing research agreements.
  • Cash position and liquidity: Cash and equivalents at year‑end increased to support the clinical development pipeline, ensuring sufficient runway for upcoming milestones in 2026 and beyond.
  • Research and development spending: R&D expenses rose in line with the expansion of the BV100 program and the initiation of Phase‑2a trials for Alpibectir, reinforcing BioVersys’ commitment to its antibacterial portfolio.

FDA Clearance for BV100 Phase‑3 Trial

On 16 March 2026, the U.S. Food and Drug Administration granted a “green light” for the Phase‑3 pivotal study of BV100 in patients with carbapenem‑resistant Acinetobacter baumannii infections. The study, designated RIV‑TARGET (NCT07326540), is a randomized, double‑blind, placebo‑controlled trial evaluating BV100 in HABP/VABP settings. The approval allows the company to:

  1. Recruit participants in the United States and commence the pivotal study as scheduled.
  2. Collect robust clinical data necessary for potential regulatory submissions to the FDA and other authorities.

The clearance follows successful completion of Phase‑2 and early Phase‑3 data demonstrating safety and efficacy of BV100 in a global cohort of patients with resistant pneumonia.

Market Context

The Swiss market index (SPI) experienced a modest gain on Monday, 16 March 2026, closing at 17,938.91 points, reflecting general investor confidence in the health‑care sector. BioVersys’ share price, trading at 27.8 CHF on 16 March 2026, remains within the 52‑week range of 21.2 CHF to 36.6 CHF. The company’s market capitalization is approximately 163 million CHF.

Pipeline Overview

  • BV100 – Phase‑3 for HABP/VABP, recently cleared by the FDA.
  • BV200 – Phase‑2a for atopic dermatitis caused by Staphylococcus aureus.
  • BV500 – Phase‑2a for non‑tuberculous mycobacteria, with a license‑option agreement with Shionogi & Co., Ltd. for further development.
  • Alpibectir – Phase‑2a for pulmonary tuberculosis.

These assets reinforce BioVersys’ focus on multi‑drug‑resistant bacterial infections and support the company’s long‑term growth strategy.

Summary

BioVersys AG’s 2025 financial results demonstrate stable revenue growth and sufficient liquidity to fund its antibacterial development program. The recent FDA clearance for BV100’s Phase‑3 trial marks a pivotal milestone in the company’s pursuit of a treatment for resistant pneumonia. The company’s continued investment in clinical development, combined with a supportive market environment, positions BioVersys to advance its pipeline toward regulatory approval and commercialization.